Showing 120 of 120on this page. Filters & sort apply to loaded results; URL updates for sharing.120 of 120 on this page
FDA Approves Everest's Nefecon for IgA Nephropathy Treatment
Nefecon in IgA Nephropathy, the Nefigard trial — NephJC
Exploring Novel Adverse Events of Nefecon - Kidney International Reports
Nefecon filed with EMA for primary IgA Nephropathy - Calliditas ...
Nefecon in IgA nephropathy: real-world renal efficacy, safety profile ...
Full article: Nefecon (Targeted-Release Formulation-Budesonide) for the ...
Nefecon For IgA Nephropathy Treatment | CheckRare
(PDF) Cost-Effectiveness Analysis of Nefecon versus Best Supportive ...
WCN24-1777 NEFECON TREATMENT PROVIDES KIDNEY BENEFITS FOR PATIENTS WITH ...
Efficacy and Safety of Nefecon in Patients with IgA Nephropathy from ...
Frontiers | Efficacy and safety of Nefecon in IgA nephropathy: real ...
Nefecon ( Budesonide ): a targeted-release formulation for Primary IgA ...
FDA Approval of Nefecon for Primary Immunoglobulin A Nephropathy Treatment
Singapore HSA Accepts Everest Medicines' Nefecon Application for IgA ...
Everest Medicines' Partner Calliditas Therapeutics Announces Nefecon ...
Nefecon para nefropatia por IgA na China e em Singapura | Netfarma
Everest Medicines' Nefecon Receives Full Approval from South Korea's ...
Calliditas’ NefIgArd study of Nefecon meets primary endpoint
Cost-effectiveness analysis - Nefecon v best supportive care | CEOR
Summary of Nefecon Benefits (Over a Lifetime Horizon) | Download ...
WCN24-1774 eGFR DECLINE IN PATIENTS WITH IgAN TREATED WITH NEFECON OR ...
Everest Medicines' Nefecon Granted Full Approval by Taiwan's TFDA for ...
Nefecon III期临床研究完整结果公布啦！治疗IgA肾病获益结果一览 来源：肾医线近日，第60届欧洲肾脏协会（ERA）年会在意大利米兰 ...
Nefecon（耐赋康，布地奈德迟释胶囊）Kinpeygo | 博鳌乐城国际药械
IgA肾病(IgAN)疗法！美国FDA推迟Nefecon(定点靶向释放布地奈德)决定日期：具有疾病修正潜力! - 专区 - 生物谷
Breaking new ground with a late-phase rare-disease pipeline
别再弄错！不是所有“布地奈德”都能治IgA肾病 - 知乎
口服类固醇Nefecon治疗原发性IgA肾病，达到III期关键临床终点-MedSci.cn
Full article: Insights on Nefecon®, a Targeted-Release Formulation of ...
2023年第17届东京IgA肾病国际研讨会热点速递__凤凰网
IgA肾病(IgAN)疗法！美国FDA授予Nefecon(定点靶向释放布地奈德)优先审查：具有疾病修正潜力! - FDA信息专区 - 生物谷
(PDF) Insights on Nefecon, a Targeted-Release Formulation of Budesonide ...
Targeted-release budesonide modifies key pathogenic biomarkers in ...
Insights on Nefecon®, a Targeted-Release Formulation of Budesonide and ...
Nefecon’s as a locally acting oral corticosteroid | DDDT
Efficacy and safety of a targeted-release formulation of budesonide in ...
Results from part A of the multi-center, double-blind, randomized ...
Everest Medicines Announces NEFECON®, the World’s First Approved ...
Everest Medicines Announces Acceptance of Nefecon® New Drug ...
Expected and verified benefits from old and new corticosteroid ...
Calliditas Announces Open Label Extension Results for Budesonide ...
June 7, 2001 Pharmaceuticals Trademarks :: Trademark Resources ...
Everest Medicines Announces South Korea Grants Fast Track Review ...
PHARMACOSERÍAS Marketing Farmacéutico/Pharmaceutical Marketing: Trece ...
云顶新耀线上论坛：IgA肾病和该疾病首创的治疗药物Nefecon在中国的治疗前景和市场机会_财富号_东方财富网
10亿美元：旭化成拟收购Calliditas，云顶新耀拥有其核心管线Nefecon大中华区权益 Armstrong 2024年5月28日，日本 ...
NefIgArd trial : Visual Abstract — NephJC
ERA 2023｜Nefecon III期临床研究完整结果公布啦！治疗IgA肾病获益结果一览_腾讯新闻
创新药企竞逐IgA肾病赛道：从机制研究到高端制剂革新
全球唯一IgA肾病对因治疗药物Nefecon(耐赋康)落地博鳌
Everest Medicines' NEFECON® sNDA Accepted by China’s NMPA, Paving the ...
创新药周报：Nefecon欧盟上市，关注IgA肾病领域进展
Everest Medicines' NEFECON®: A Breakthrough in IgA Nephropathy ...
[데일리팜] 식약처 GIFT 2호 \'네페콘\' 허가...신규 적응증 개발
Nefecon-Nefecon中文说明书,价格,哪里有卖-香港济民药业
最新综述 | 一文读懂Nefecon如何对因治疗IgA肾病，显著降低蛋白尿，延缓疾病进展_腾讯新闻
China Grants Full Approval to Everest Medicines’ NEFECON® as First and ...
Neocon B Tablets – Medishop.pk
【IgA肾病药物「布地奈德肠溶胶囊」在国内获完全批准】2025年5月7日，云顶新耀宣布其布地奈德肠溶胶囊（Budesonide、Nefecon ...
Nefonex 30 Mg Tablets at ₹ 175/box | Paracetamol Tablets in Ambala | ID ...
肾医线-首页
Everest Medicines Gains TFDA Approval for NEFECON® to Treat IgA ...
Tarek Abbas on LinkedIn: Long-term renal benefit over 2 years with ...
Healing, Hype, or Harm: The NefIgArd trial — NephJC
2023年第17届东京IgA肾病国际研讨会热点速递_Gd-IgA_Nefecon_水平
Everest Medicines' NEFECON® Approval in China: A Catalyst for Dominance ...
Everest Medicines Partner Calliditas Publish P-III (NeflgArd) Trial ...
【布地奈德,布地奈德肠溶胶囊,耐赋康,budesonide,Tarpeyo,Nefecon,Kinpeygo（欧版）】说明书_代购价格_印度 ...
云顶新耀宣布中国国家药品监督管理局受理Nefecon用于治疗原发性IgA肾病的新药上市许可申请医药新闻-ByDrug-一站式医药资源共享中心-医药魔方
Everest medicines announces Taiwan TFDA approval of NEFECON® for the ...
全球首款IgA 肾病治疗药物！云顶新耀与 Calliditas共同开发的Nefecon的3期研究取得积极顶线结果_腾讯新闻
肾病患者的福音！口服类固醇Nefecon向FDA递交上市申请，治疗IgA肾病 - 药时代DrugTimes
医趋势-Nefecon有望成为50年来首个IgA肾病的靶向治疗药物
